Bharat Immunologicals & Biologicals Corporation Limited

Equities

524663

INE994B01014

Pharmaceuticals

Market Closed - Bombay S.E. 06:20:06 2024-04-26 am EDT 5-day change 1st Jan Change
32.16 INR -2.22% Intraday chart for Bharat Immunologicals & Biologicals Corporation Limited +8.36% -9.02%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
EU countries agree to admit travellers vaccinated with WHO-approved shots RE
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter Ended December 31, 2021 CI
EU proposes booster jabs for 2022 travel, opens to WHO vaccines RE
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter Ended September 30, 2021 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2021 CI
Bharat Immunologicals & Biologicals : to Receive Indian Government Funding for COVID Vaccine Production MT
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Full Year Ended March 31, 2020 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Third Quarter Ended December 31, 2019 CI
Bharat Immunologicals & Biologicals Corp. Ltd. Reports Earnings Results for the Second Quarter Ended September 30, 2019 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the First Quarter Ended June 30, 2019 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019 CI
Bharat Immunologicals & Biologicals Corp. Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2018 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended September 30, 2018 CI
Bharat Immunologicals & Biologicals Corporation Limited Announces Unaudited Earnings Results for the First Quarter Ended June 30, 2018 CI
Bharat Immunologicals & Biologicals Corporation Limited Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2018 CI
Bharat Immunologicals & Biologicals Corporation Limited Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2017 CI
Chart Bharat Immunologicals & Biologicals Corporation Limited
More charts
Bharat Immunologicals and Biologicals Corporation Limited is an India-based biotechnology company. The Company is primarily engaged in the manufacture of oral polio vaccine, zinc tablet, and diarrhea management kit. It operates under various segment, namely oral polio vaccine, zinc tablets, BIB VIT, and BIBSANIT. It is also focused on manufacturing Ready to Use Therapeutic Food (RUTF), which is used for the treatment of malnourishment among various acute malnourished children. The Company is switched over to bivalent oral polio vaccine (bOPV) from trivalent oral polio vaccine (tOPV). It is also diversified into plasma-derived medicines and Oral Cholera vaccines. The Company's manufacturing unit is located at Village Chola, Bulandshahr, Uttar Pradesh, India.
More about the company
  1. Stock Market
  2. Equities
  3. 524663 Stock
  4. News Bharat Immunologicals & Biologicals Corporation Limited
  5. Bharat Immunologicals & Biologicals : to Receive Indian Government Funding for COVID Vaccine Production